Atherosclerosis: Recent trials, new targets and future directions

International Journal of Cardiology

Volumn 192, Issue , 2015, Pages 72-81

  Ladeiras Lopes, Ricardo ^a,b   Agewall, Stefan ^c   Tawakol, Ahmed ^d,e   Staels, Bart ^f   Stein, Evan ^g   Mentz, Robert J ^h   Leite Moreira, Adelino ^a   Zannad, Faiez ⁱ   Koenig, Wolfgang ^j,k,l  

^a University of Porto   (Portugal)

^b Gaia/Espinho Hospital Center   (Portugal)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f INSERM UMR1011 Univ Lille 2 Institut Pasteur de Lille EGID ^*  (France)

^g Metabolic and Atherosclerosis Research Centre   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j UNIVERSITY HOSPITAL ULM   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

more..

Author keywords

Atherosclerosis; Clinical research; Pharmacology

Indexed keywords

ALIROCUMAB; ANACETRAPIB; APABETALONE; APOLIPOPROTEIN A1; ATORVASTATIN; BOCOCIZUMAB; C REACTIVE PROTEIN; CANAKINUMAB; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; DARAPLADIB; EVACETRAPIB; EVOLOCUMAB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FOLIC ACID; LAROPIPRANT; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; NICOTINIC ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB;

ADD ON THERAPY; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN METABOLISM; MORTALITY; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STUDY DESIGN; MOLECULARLY TARGETED THERAPY;

ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84930934403     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.013     Document Type: Review

References (126)

1. A.D. Lopez, C.D. Mathers, M. Ezzati, D.T. Jamison, and C.J. Murray Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data Lancet 367 2006 1747 1757
2. U. Laufs, W.S. Weintraub, and C.J. Packard Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34 2013 2660 2665
3. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, and C. Pollicino Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
4. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
5. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, and R. Ceska The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K
6. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, and R.H. Eckel 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl. 2 2013 S1 S45
7. P. Kirchhof, K.R. Sipido, M.R. Cowie, T. Eschenhagen, K.A. Fox, and H. Katus The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology Eur Heart J 35 2014 3250 3257
8. L.J. Wang, and B.L. Song Niemann-Pick C1-Like 1 and cholesterol uptake Biochim Biophys Acta 1821 2012 964 972
9. I. Ramasamy Recent advances in physiological lipoprotein metabolism Clin Chem Lab Med 2013 1 33 CCLM / FESCC
10. E. Dembowski, and M.H. Davidson Statin and ezetimibe combination therapy in cardiovascular disease Curr Opin Endocrinol Diabetes Obes 16 2009 183 188
11. J.J. Kastelein, F. Akdim, E.S. Stroes, A.H. Zwinderman, M.L. Bots, and A.F. Stalenhoef Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
12. C.P. Cannon IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes 2014
13. D. Urban, J. Poss, M. Bohm, and U. Laufs Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis J Am Coll Cardiol 62 2013 1401 1408
14. K.R. Feingold, A.H. Moser, J.K. Shigenaga, S.M. Patzek, and C. Grunfeld Inflammation stimulates the expression of PCSK9 Biochem Biophys Res Commun 374 2008 341 344
15. Z. Tang, L. Jiang, J. Peng, Z. Ren, D. Wei, and C. Wu PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages Int J Mol Med 30 2012 931 938
16. Z. Awan, N.G. Seidah, J.G. MacFadyen, S. Benjannet, D.I. Chasman, and P.M. Ridker Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial Clin Chem 58 2012 183 189
17. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
18. F. Raal, R. Scott, R. Somaratne, I. Bridges, G. Li, and S.M. Wasserman Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
19. E.A. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, and R. Dufour Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
20. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
21. E.A. Stein, S. Mellis, G.D. Yancopoulos, N. Stahl, D. Logan, and W.B. Smith Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
22. J.J.P. Kastelein, H.N. Ginsberg, G.G.K.H. Langslet, R. Ceska, and R. Dufour Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: Results of ODYSSEY FH I and FH II studies 2014
23. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, and F. Huang Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
24. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, and L. Lei Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
25. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
26. C.P. Cannon, B. Cariou, D. Blom, J. McKenney, C. Lorenzato, and R. Pordy Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study 2014
27. D. Sullivan, A.G. Olsson, R. Scott, J.B. Kim, A. Xue, and V. Gebski Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
28. U.S. National Institutes of Health Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) 2013
29. U.S. National Institutes of Health ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab 2012
30. U.S. National Institutes of Health The Evaluation Of PF-04950615 (RN316), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-1) 2013
31. U.S. National Institutes of Health The Evaluation Of PF-04950615 (RN316) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects (SPIRE-2) 2013
32. J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, and M.R. Averna Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients 2014
33. D.J. Blom, T. Hala, M. Bolognese, M.J. Lillestol, P.D. Toth, and L. Burgess A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
34. J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, and M. Averna Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events N Engl J Med 372 2015 1489 1499
35. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, F.J. Raal, D.J. Blom, and J. Robinson Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events N Engl J Med 372 2015 1500 1509
36. M.M. Hussain, J. Shi, and P. Dreizen Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly J Lipid Res 44 2003 22 32
37. J.R. Wetterau, L.P. Aggerbeck, M.E. Bouma, C. Eisenberg, A. Munck, and M. Hermier Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia Science 258 1992 999 1001
38. M. Cuchel, E.A. Meagher, H. du Toit Theron, D.J. Blom, A.D. Marais, and R.A. Hegele Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
39. F.F. Samaha, J. McKenney, L.T. Bloedon, W.J. Sasiela, and D.J. Rader Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia Nat Clin Pract Cardiovasc Med 5 2008 497 505
40. M. Cuchel, L.T. Bloedon, P.O. Szapary, D.M. Kolansky, M.L. Wolfe, and A. Sarkis Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
41. M. Shiomi, and T. Ito MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion Eur J Pharmacol 431 2001 127 131
42. K. Ueshima, H. Akihisa-Umeno, A. Nagayoshi, S. Takakura, M. Matsuo, and S. Mutoh Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation Biol Pharm Bull 28 2005 247 252
43. C.E. Chandler, D.E. Wilder, J.L. Pettini, Y.E. Savoy, S.F. Petras, and G. Chang CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans J Lipid Res 44 2003 1887 1901
44. E. Kim, S. Campbell, O. Schueller, E. Wong, B. Cole, and J. Kuo A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile J Pharmacol Exp Ther 337 2011 775 785
45. M.M. Hussain, P. Rava, M. Walsh, M. Rana, and J. Iqbal Multiple functions of microsomal triglyceride transfer protein Nutr Metab 9 2012 14
46. C.F. Bennett, and E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu Rev Pharmacol Toxicol 50 2010 259 293
47. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, and W.C. Cromwell Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
48. E.A. Stein, R. Dufour, C. Gagne, D. Gaudet, C. East, and J.M. Donovan Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
49. M.P. McGowan, J.C. Tardif, R. Ceska, L.J. Burgess, H. Soran, and I. Gouni-Berthold Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006
50. I.S.I.S. Pharmaceuticals ISIS-APOCIII Rx 2014
51. I.S.I.S. Pharmaceuticals ISIS-APO(a)Rx 2013
52. E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, and A. Thompson Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
53. R. Frikke-Schmidt, B.G. Nordestgaard, M.C. Stene, A.A. Sethi, A.T. Remaley, and P. Schnohr Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease JAMA 299 2008 2524 2532
54. C.L. Haase, A. Tybjaerg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard, and R. Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals J Clin Endocrinol Metab 97 2012 E248 E256
55. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, and M.K. Jensen Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
56. S. Acharjee, W.E. Boden, P.M. Hartigan, K.K. Teo, D.J. Maron, and S.P. Sedlis Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol 62 2013 1826 1833
57. A.P. van de Woestijne, Y. van der Graaf, A.H. Liem, M.J. Cramer, J. Westerink, and F.L. Visseren Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication J Am Coll Cardiol 62 2013 1834 1841
58. P.M. Ridker, J. Genest, S.M. Boekholdt, P. Libby, A.M. Gotto, and B.G. Nordestgaard HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
59. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, and E. Braunwald Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
60. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, and J. Brumm Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
61. C. Besler, T.F. Luscher, and U. Landmesser Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease EMBO Mol Med 4 2012 251 268
62. R.S. Rosenson, H.B. Brewer Jr., B. Ansell, P. Barter, M.J. Chapman, and J.W. Heinecke Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges Circulation 128 2013 1256 1267
63. O. Quehenberger, and E.A. Dennis The human plasma lipidome N Engl J Med 365 2011 1812 1823
64. S. Mora, R.J. Glynn, and P.M. Ridker High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy Circulation 128 2013 1189 1197
65. A.V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, and K. Jafri Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
66. B. Shao, C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, and N. Brot Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase Circ Res 114 2014 1733 1742
67. E. Cavusoglu, C. Ruwende, C. Eng, V. Chopra, S. Yanamadala, and L.T. Clark Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome Am J Cardiol 99 2007 1364 1368
68. G. Ndrepepa, S. Braun, J. Mehilli, N. von Beckerath, A. Schomig, and A. Kastrati Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes Eur J Clin Invest 38 2008 90 96
69. H. Scharnagl, M.E. Kleber, B. Genser, S. Kickmaier, W. Renner, and G. Weihrauch Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography-the LURIC study Int J Cardiol 174 2014 96 105
70. N. Lu, S. Xie, J. Li, R. Tian, and Y.Y. Peng Myeloperoxidase-mediated oxidation targets serum apolipoprotein A-I in diabetic patients and represents a potential mechanism leading to impaired anti-apoptotic activity of high density lipoprotein Clin Chim Acta 441 2015 163 170
71. M.J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur Heart J 31 2010 149 164
72. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, and K. Koprowicz Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
73. HPS2-THRIVE Collaborative Group, M.J. Landray, R. Haynes, J.C. Hopewell, S. Parish, and T. Aung Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
74. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
75. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
76. P.J. Barter, H.B. Brewer Jr., M.J. Chapman, C.H. Hennekens, D.J. Rader, and A.R. Tall Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 160 167
77. P.J. Barter, and J.J. Kastelein Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease J Am Coll Cardiol 47 2006 492 499
78. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
79. U.S. National Institutes of Health REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification 2010
80. U.S. National Institutes of Health A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE) 2012
81. D. Bailey, R. Jahagirdar, A. Gordon, A. Hafiane, S. Campbell, and S. Chatur RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
82. S. Picaud, C. Wells, I. Felletar, D. Brotherton, S. Martin, and P. Savitsky RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain Proc Natl Acad Sci U S A 110 2013 19754 19759
83. S.J. Nicholls, A. Gordon, J. Johansson, K. Wolski, C.M. Ballantyne, and J.J. Kastelein Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J Am Coll Cardiol 57 2011 1111 1119
84. S.J. Nicholls, C.M. Ballantyne, P.J. Barter, H.B. Brewer, J.J.P. Kastelein, and A. Gordon Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study 2013
85. C.R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, and J. Johansson Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 2001 1949 1954
86. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, and M. Yasin Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
87. J.C. Tardif, C.M. Ballantyne, P. Barter, J.L. Dasseux, Z.A. Fayad, and M.C. Guertin Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial Eur Heart J 35 2014 3277 3286
88. B.R. Krause, and A.T. Remaley Reconstituted HDL for the acute treatment of acute coronary syndrome Curr Opin Lipidol 24 2013 480 486
89. K.J. Rayner, C. Fernandez-Hernando, and K.J. Moore MicroRNAs regulating lipid metabolism in atherogenesis Thromb Haemost 107 2012 642 647
90. I. Andreou, X. Sun, P.H. Stone, E.R. Edelman, and M.W. Feinberg miRNAs in atherosclerotic plaque initiation, progression, and rupture Trends Mol Med 21 2015 307 318
91. J. Ren, J. Zhang, N. Xu, G. Han, Q. Geng, and J. Song Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease PLoS One 8 2013 e80738
92. K.J. Rayner, C.C. Esau, F.N. Hussain, A.L. McDaniel, S.M. Marshall, and J.M. van Gils Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides Nature 478 2011 404 407
93. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
94. C. Weber, and H. Noels Atherosclerosis: current pathogenesis and therapeutic options Nat Med 17 2011 1410 1422
95. E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A(2) in vascular disease Circ Res 89 2001 298 304
96. P.W. Serruys, H.M. Garcia-Garcia, P. Buszman, P. Erne, S. Verheye, and M. Aschermann Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
97. H.D. White, C. Held, R. Stewart, E. Tarka, R. Brown, and R.Y. Davies Darapladib for preventing ischemic events in stable coronary heart disease N Engl J Med 370 2014 1702 1711
98. M.L. O'Donoghue, E. Braunwald, H.D. White, D.P. Steen, M.A. Lukas, and E. Tarka Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial JAMA 312 2014 1006 1015
99. R.S. Rosenson, C. Hislop, D. McConnell, M. Elliott, Y. Stasiv, and N. Wang Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 2009 649 658
100. R.S. Rosenson, M. Elliott, Y. Stasiv, and C. Hislop Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease Eur Heart J 32 2011 999 1005
101. R.S. Rosenson, C. Hislop, M. Elliott, Y. Stasiv, M. Goulder, and D. Waters Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients J Am Coll Cardiol 56 2010 1079 1088
102. S.J. Nicholls, J.J. Kastelein, G.G. Schwartz, D. Bash, R.S. Rosenson, and M.A. Cavender Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial JAMA 311 2014 252 262
103. M.V. Holmes, T. Simon, H.J. Exeter, L. Folkersen, F.W. Asselbergs, and M. Guardiola Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study J Am Coll Cardiol 62 2013 1966 1976
104. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605
105. B.M. Everett, A.D. Pradhan, D.H. Solomon, N. Paynter, J. Macfadyen, and E. Zaharris Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis Am Heart J 166 2013 199 207
106. G.K. Hansson, and J. Nilsson Vaccination against atherosclerosis? Induction of atheroprotective immunity Semin Immunopathol 31 2009 95 101
107. P. Sjogren, G.N. Fredrikson, A. Samnegard, C.G. Ericsson, J. Ohrvik, and R.M. Fisher High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction Eur Heart J 29 2008 2218 2226
108. S. Burgess, A. Butterworth, and S.G. Thompson Mendelian randomization analysis with multiple genetic variants using summarized data Genet Epidemiol 37 2013 658 665
109. C.J. Willer, S. Sanna, A.U. Jackson, A. Scuteri, L.L. Bonnycastle, and R. Clarke Newly identified loci that influence lipid concentrations and risk of coronary artery disease Nat Genet 40 2008 161 169
110. G. Thanassoulis Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease Can J Cardiol 29 2013 30 36
111. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
112. J. Zacho, A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
113. R. Clarke, D.A. Bennett, S. Parish, P. Verhoef, M. Dotsch-Klerk, and M. Lathrop Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias PLoS Med 9 2012 e1001177
114. A.D. Hingorani, and J.P. Casas The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis Lancet 379 2012 1214 1224
115. N. Sarwar, A.S. Butterworth, D.F. Freitag, J. Gregson, P. Willeit, and D.N. Gorman Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies Lancet 379 2012 1205 1213
116. R. Duivenvoorden, E. de Groot, E.S. Stroes, and J.J. Kastelein Surrogate markers in clinical trials-challenges and opportunities Atherosclerosis 206 2009 8 16
117. R. Puri, E.M. Tuzcu, S.E. Nissen, and S.J. Nicholls Exploring coronary atherosclerosis with intravascular imaging Int J Cardiol 168 2013 670 679
118. S. Agewall, E. DeGroot, P. Marcos-Alberca, J.L. Zamorano, A.A. Barrero, and L.P. Badano Ultrasound and radiology surrogate endpoints in pharmacological studies Atherosclerosis 224 2012 12 24
119. S.W. Murray, R.H. Stables, H.M. Garcia-Garcia, A.D. Grayson, M.A. Shaw, and R.A. Perry Construction and validation of a plaque discrimination score from the anatomical and histological differences in coronary atherosclerosis: the Liverpool IVUS-V-HEART (Intra Vascular UltraSound-Virtual-Histology Evaluation of Atherosclerosis Requiring Treatment) study EuroIntervention 10 2014 815 823
120. P.G. Camici, O.E. Rimoldi, O. Gaemperli, and P. Libby Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque Eur Heart J 33 2012 1309 1317
121. M.W. Lorenz, J.F. Polak, M. Kavousi, E.B. Mathiesen, H. Völzke, and T.P. Tuomainen Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data Lancet 379 2012 2053 2062
122. R. Puri, S.E. Nissen, M. Shao, C.M. Ballantyne, P.J. Barter, and M.J. Chapman Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy Eur Heart J 34 2013 3182 3190
123. S. Takarada, T. Imanishi, K. Ishibashi, T. Tanimoto, K. Komukai, and Y. Ino The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound JACC Cardiovasc Interv 3 2010 766 772
124. G. van Soest, E. Regar, T.P. Goderie, N. Gonzalo, S. Koljenovic, and G.J. van Leenders Pitfalls in plaque characterization by OCT: image artifacts in native coronary arteries JACC Cardiovasc Imaging 4 2011 810 813
125. J.G. Robinson, and N.J. Stone Identifying patients for aggressive cholesterol lowering: the risk curve concept Am J Cardiol 98 2006 1405 1408
126. B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, and E.H. Barnes The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590